"The creativity, rigor, and collaborative nature of the science at Genentech make this a very special place. It’s inspiring to be part of a community that puts science and patients first."
I joined Genentech in 2016 as a Senior Scientific Researcher in the Cancer Immunology department, and in 2020, started my own group as a Scientist in the department. During my time at Genentech, I have continued to explore my long-standing interest in T cell biology by studying how key regulatory pathways and T cell-intrinsic properties influence the outcome of a T cell response. From identifying the critical role dendritic cells play in the PD-1/PD-L1 regulatory axis, to employing novel CRISPR-engineering technologies in the development of T cell therapies, Genentech has provided a dynamic, creative, and collaborative environment to pursue incredible science with the goal of bringing new therapeutics to patients in need.
Nature Cancer, 2020
Productive T cell responses are critical for the effective control of tumors and infections. However, fundamental questions remain about the factors that drive the development of such T cell responses, particularly in settings of chronic stimulation, such as tumors. My group is interested in better understanding how both T cell-intrinsic and -extrinsic factors influence the outcome of a T cell response. By using a combination of cellular immunology, CRISPR-engineering, and next generation sequencing approaches, we are studying how the specific properties of T cell receptors, T cell differentiation status, and the context of antigen exposure affects T cell responses against tumors.